Kyle Jenne
Corporate Officer/Principal bei IONIS PHARMACEUTICALS, INC.
Vermögen: 83 220 $ am 30.04.2024
Profil
Kyle Jenne is currently the Chief Executive Officer & Director at Elsie Biotechnologies Inc. He is also the Executive Vice President-Commercial at Ionis Pharmaceuticals, Inc. Additionally, Mr. Jenne previously worked as the Chief Commercial Officer & Executive VP at Ionis Pharmaceuticals, Inc. and as the Senior Vice President-US Commercial at Akcea Therapeutics, Inc. He completed his undergraduate degree at Arizona State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.02.2024 | 1 989 ( 0,00% ) | 83 220 $ | 30.04.2024 |
Aktive Positionen von Kyle Jenne
| Unternehmen | Position | Beginn |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29.02.2024 |
Elsie Biotechnologies Inc.
 Elsie Biotechnologies Inc. BiotechnologyHealth Technology Elsie Biotechnologies Inc. is a private company located in California that is focused on utilizing RNA therapeutics to treat diseases that were previously considered undruggable. The American company's platform enables the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. The company was founded in 2021 by Philip E. Dawson and Phil Baran, and the CEO is Kyle Jenne. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Kyle Jenne
| Unternehmen | Position | Ende |
|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ausbildung von Kyle Jenne
| Arizona State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Elsie Biotechnologies Inc. is a private company located in California that is focused on utilizing RNA therapeutics to treat diseases that were previously considered undruggable. The American company's platform enables the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. The company was founded in 2021 by Philip E. Dawson and Phil Baran, and the CEO is Kyle Jenne. | Health Technology |
